VEGFA and melanoma: Since VEGF is a relevant target in melanoma, we carried out a UK multi-centre, open-label, randomised controlled phase III trial of adjuvant bevacizumab versus standard surveillance in patients with resected cutaneous melanoma at high risk of recurrence.